Table 3.
Comparison of clinical characteristics of cyclin D1− and cyclin D1+ MCL patients from standard series published previously22
| Characteristic | Cyclin D1− | Cyclin D1+ |
|---|---|---|
| n | 40 | 71 |
| Median age, y (range) | 63 (33-90) | 63 (38-92) |
| Sex, n (%) | ||
| Male | 29 (73%) | 53 (75%) |
| Female | 11 (27%) | 18 (25%) |
| Histology, n (%) | ||
| Classic | 39 (97%)† | 58 (82%) |
| Blastoid* | 1 (3%) | 13 (18%) |
| Ann Arbor stage, n (%) | ||
| I/II | 4 (11%) | 8 (11%) |
| III/IV | 33 (89%) | 62 (89%) |
| B-symptoms | 5/19 (26%) | 25 (35%) |
| High LDH | 8/23 (35%) | 26 (37%) |
| Extranodal involvement* | 37/39 (95%) | 53/68 (78%) |
| BM involvement | 29/39 (74%) | 39 (56%) |
| IPI score, n (%) | ||
| Low-risk (0,1) | 3 (19%) | 16 (26%) |
| Intermediate-risk (2,3) | 11 (69%) | 35 (56%) |
| High-risk (4,5) | 2 (12%) | 11 (18%) |
| Therapy, n (%) | ||
| Chemotherapy | 10 (31%) | 57 (83%) |
| Rituximab or immunochemotherapy* | 19 (59%) | 9 (13%) |
| Local therapy/no treatment | 3 (10%) | 3 (4%) |
| Response to therapy (CR + PR), n (%) | 24/27 (88%) | 53/66 (80%) |
| Median survival, mo | 38 | 28 |
CR indicates complete response; LDH, lactate dehydrogenase; NR, not reached; PR, partial response, y, years; and mo, months.
*
P < .05 by χ2 test.
†
One case progressed from classical morphology to pleomorphic 4 years after diagnosis.